Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Endo_International
|
| gptkbp:acquisitionYear |
2015
|
| gptkbp:CEO |
Paul Campanelli
|
| gptkbp:foundedIn |
1978
|
| gptkbp:founder |
gptkb:Barry_Sherman
|
| gptkbp:headquartersLocation |
gptkb:Chestnut_Ridge,_New_York,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Par Pharmaceutical
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
gptkb:United_States
|
| gptkbp:numberOfEmployees |
over 1,700
|
| gptkbp:parentCompany |
gptkb:Endo_International
|
| gptkbp:productType |
prescription pharmaceuticals
oral solid dosage forms sterile injectables |
| gptkbp:specializesIn |
generic drugs
|
| gptkbp:subsidiary |
gptkb:Endo_International
|
| gptkbp:website |
https://www.parpharm.com/
|
| gptkbp:bfsParent |
gptkb:Endo_International
gptkb:TPG_Capital,_L.P. |
| gptkbp:bfsLayer |
7
|